TOKYO (Reuters) – Takeda Pharmaceutical Co (T:) has agreed to sell its Japanese consumer healthcare business to U.S. investment fund Blackstone Group (N:) for 242 billion yen ($2.3 billion), Japan’s largest drugmaker said on Monday.
The sale of Takeda Consumer Healthcare Company, which makes over-the-counter (OTC) drugs and health products, is expected to close by March 31, subject to regulatory closing conditions, the company said in a statement.
Takeda has been reducing its OTC assets worldwide as it seeks to refocus its business and reduce debt after its $59 billion acquisition of Shire.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.